03, November 2011

ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA

ImmuPharma PLC (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to provide an update on the development status o...

Click here for more details

21, October 2011

ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger

ImmuPharma PLC (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce that following discussions with Cephalon I...

Click here for more details